A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Erenumab-Aooe (AIMOVIG)

AIMOVIG is indicated for the preventive treatment of migraine in adults.

First FDA approval2018-05-22
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$451.9M in CY2024 Part D spend498K claims · 101K beneficiaries · 329 plans surveyed

Lowest NADAC
$753.28/unit
2 NDCs benchmarked, lowest of all strengths.
Average NADAC
$753.61
Across all dosage forms in distribution.
Highest NADAC
$753.94
Range is tight.
Plans with PA
590 / 329
Substantial PA friction across plans.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Erenumab-Aooe used for?

AIMOVIG is indicated for the preventive treatment of migraine in adults.

Is there a generic for Erenumab-Aooe?

No. Erenumab-Aooe is brand-only with no generic equivalents currently in market.

How much does my plan pay for Erenumab-Aooe?

Across 329 Part D plans, Erenumab-Aooe averages $753.61/unit (NADAC). Lowest available: $753.28/unit. Highest in distribution: $753.94/unit.

Is Erenumab-Aooe on the FDA shortage list?

No. Erenumab-Aooe is not currently on the FDA Drug Shortage Database.

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (2 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.